Skiplinks


Breadcrumb

[A14-05] Sofosbuvir - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Overview

Overview

Commission:Commission awarded on 2014-01-21 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department:Drug Assessment
Current document:PDFExtract of dossier assessment [PDF, 344 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects:[A14-20] Addendum to Commission A14-05 (sofosbuvir)
Status: Commission completed

[A16-48] Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2014-05-02Extract of dossier assessment344 kBPDFdownload file
2014-05-02Dossier assessment (German version)859 kBPDFdownload file


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance


to top

Glossary entries